Tigris Pharmaceuticals, Inc. is a venture-backed clinical-stage biopharmaceutical company that commercially develops innovative products for the treatment of important unmet medical needs in cancer and infectious diseases. Tigris is focusing its efforts on the development, testing and commercialization of its lead compound, A-007, as a non-invasive treatment for both pre-cancerous HPV-induced lesions and for invasive epithelial cancers. A key component of Tigris' strategy is to acquire global rights to additional product candidates in oncology and infectious diseases, while continuing to use its technology platform to develop and commercialize new products and line extensions.
